ライフサイエンスコーパス: fumarate

1 avirenz, emtricitabine, tenofovir disoproxil fumarate).

2 ment, hypertension, and tenofovir disoproxil fumarate.

3 e hydratase (FH) causes hyperaccumulation of fumarate.

4 sing oral emtricitabine-tenofovir disoproxil fumarate.

5 in water to produce hyperpolarized [1-(13)C]fumarate.

6 tor, emtricitabine, and tenofovir disoproxil fumarate.

7 enz, emtricitabine, and tenofovir disoproxil fumarate.

8 se of emtricitabine and tenofovir disoproxil fumarate.

9 enofovir alafenamide to tenofovir disoproxil fumarate.

10 the accumulation of the TCA cycle metabolite fumarate.

11 efavirenz/emtricitabine/tenofovir disoproxil fumarate.

12 than emtricitabine and tenofovir disoproxil fumarate.

13 terval [CI] 0.56-0.96), tenofovir disoproxil fumarate (0.68, 95% CI 0.49-0.95), and lopinavir (0.64,

14 atively associated with tenofovir disoproxil fumarate (0.71, 95% CI 0.51-0.99).

15 fixed-dose combination tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and once-daily

16 standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 m

17 xed-dose combination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600

18 lutegravir (50 mg) plus tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg).

19 ricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, with matched placebo ta

20 icitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo, once daily for

21 icitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo.

22 nued therapy containing tenofovir disoproxil fumarate (300 mg).

23 r placebo for 90 days followed by clemastine fumarate (5.36 mg orally twice daily) for 60 days (group

24 umber generator to receive either clemastine fumarate (5.36 mg orally twice daily) for 90 days follow

25 with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%).

26 h more weight gain than tenofovir disoproxil fumarate, abacavir, or zidovudine.

27 or understanding the proteomic adaptation to fumarate accumulation and a foundation for future effort

28 ecific Fh1 deletion (resulting in endogenous fumarate accumulation and a genetic TCA cycle block refl

29 ignant form of renal cancer characterized by fumarate accumulation and increased production of reacti

30 Although it is known that fumarate accumulation can alter cellular signaling, if a

31 n this study, we demonstrate that endogenous fumarate accumulation upregulates surface expression of

32 ypes, indicating the causal role of cellular fumarate accumulation.

33 stable TM homodimer in both the inactive and fumarate-activated state of DcuS.

34 eric state of the linker was relieved during fumarate activation of DcuS, indicating structural rearr

35 Fumarate, an electron acceptor in anaerobic respiration

36 s an enzyme that catalyses the degradatin of fumarate, an inhibitor of glycolysis.

37 ied/mixed plaque, while tenofovir disoproxil fumarate and efavirenz were negatively associated with a

38 turally similar EDO ligands such as dimethyl fumarate and electron-deficient styrenes afford primaril

39 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure pro

40 afety in Korea approved tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) co-formulate for us

41 monotherapy or combined tenofovir disoproxil fumarate and emtricitabine and whether the benefits vary

42 that also includes oral tenofovir disoproxil fumarate and emtricitabine as an option.

43 uct in addition to oral tenofovir disoproxil fumarate and emtricitabine as compared with oral PrEP al

44 navir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a day (atazanavir group)

45 ective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies on optimal adherence,

46 lamivudine tablets and tenofovir disoproxil fumarate and emtricitabine tablets were over-encapsulate

47 prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strat

48 -inferior to daily oral tenofovir disoproxil fumarate and emtricitabine.

49 r can also catalyze the reduction of soluble fumarate and heterogenous graphene oxide, with electrons

50 and bone toxicity than tenofovir disoproxil fumarate and might improve the long-term safety of antir

51 ate, increased levels of sucrose, malate and fumarate and minor changes in total protein and starch l

52 to an ancillary and unannotated lack of the fumarate and nitrate reduction (FNR) anaerobic regulator

53 brane resulting in rapid efflux of succinate/fumarate and other dicarboxylates capable of competitive

54 significant increase in the concentration of fumarate and phenylalanine in stored salmon muscle.

55 these findings identify GSDMD as a target of fumarate and reveal a mechanism of action for fumarate-b

56 powder (MNP) containing a mixture of ferrous fumarate and sodium iron EDTA (FeFum+NaFeEDTA) in Kenyan

57 R, FrdABCD) catalyzes the interconversion of fumarate and succinate at a covalently attached FAD with

58 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide conferred potentially

59 In contrast, tenofovir disoproxil fumarate and tenofovir alafenamide treatment gave rise t

60 We quantified tenofovir disoproxil fumarate and tenofovir concentrations in cervicovaginal

61 We used an oral treatment with dimethyl fumarate and the HCAR2 endogenous ligand beta-hydroxybut

62 ion of oncometabolites (including succinate, fumarate and total 2HG) and other tricarboxylic acid cyc

63 ived oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated.

64 implications of oncometabolites [succinate, fumarate, and 2-hydroxyglutarate (2HG)] in cancer pathog

65 cosubstrate and are inhibited by succinate, fumarate, and 2-hydroxyglutarate.

66 RT; combined efavirenz, tenofovir disoproxil fumarate, and emtricitabine).

67 afine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; fixed t

68 antly increased: creatine, dehydroascorbate, fumarate, and succinate in trauma patients who developed

69 ater TF activity, while tenofovir disoproxil fumarate- and tenofovir alafenamide-treated cells and EM

70 Systemic administration of monomethyl fumarate, another agonist of the nicotinic acid receptor

71 reatly accelerated preclinical studies using fumarate as a biomarker.

72 nalyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple scler

73 ved hydrogen (H(2)) as an electron donor and fumarate as an electron acceptor.

74 We extended these observations by defining fumarate as an inhibitor of pyroptotic cell death.

75 ion of reactive oxygen species, highlighting fumarate as an oncometabolite.

76 g Administration approved use of bedaquiline fumarate as part of combination therapy for multidrug-re

77 ministration approved the use of bedaquiline fumarate as part of combination therapy for treatment of

78 sing inexpensive cyclopentadiene and diethyl fumarate as starting materials.

79 during bacterial anaerobic respiration with fumarate as the terminal electron acceptor.

80 C4-dicarboxylates aspartate and malate into fumarate (AspA, FumABC), are required for fumarate/H(2)-

81 started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March

82 wever, it is no more effective than dimethyl fumarate at reducing the barrier to Csp(3)-Csp(3) reduct

83 ative individuals using tenofovir disoproxil fumarate-based pre-exposure prophylaxis for the preventi

84 umarate and reveal a mechanism of action for fumarate-based therapeutics that include DMF, for the tr

85 nefit of PrEP with oral tenofovir disoproxil fumarate-based therapy to reduce the risk of acquisition

86 n is commonly used to produce hyperpolarized fumarate, but a cheaper and faster alternative is to pro

87 Thus, S. Typhimurium obtains fumarate by DcuABC-mediated import and conversion of L-m

88 In agreement with this, accumulation of fumarate by the therapeutic drug dimethyl fumarate (DMF)

89 Hyperpolarized fumarate can be used as a probe of real-time metabolism

90 Fumarate can complex with GSH and thereby exhaust cells

91 igodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyt

92 the other hand, downregulating PCK2 hindered fumarate carbon flows in TCA cycle, leading to attenuate

93 They further demonstrated that fumarate changes FrdA's conformation to one that can bin

94 inal challenge similar to FTC/TFV disoproxil fumarate combination in the macaque model.

95 3, Mia40, and Erv1, the addition of Osm1 and fumarate completes the disulfide exchange pathway that r

96 ion can alter cellular signaling, if and how fumarate confers a growth advantage remain unclear.

97 7.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recomme

98 60 years or older, on a tenofovir disoproxil fumarate-containing regimen and were randomly assigned (

99 iron supplementation (60 mg iron as ferrous fumarate daily).

100 PASP across the full TM region, whereas the fumarate-destabilized linker dimer converts the signal o

101 of fumarate by the therapeutic drug dimethyl fumarate (DMF) also promotes ULBP2/5 surface expression.

102 r 75 mg twice daily), or open-label dimethyl fumarate (DMF) as a reference.

103 We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate

104 We show here that dimethyl fumarate (DMF) dose-dependently induces mitochondrial bi

105 tudy was to explore the efficacy of dimethyl fumarate (DMF) in preventing disease reactivation after

106 (4-OI) and the clinically approved dimethyl fumarate (DMF) induce a cellular antiviral program that

107 Dimethyl fumarate (DMF) is a prescribed treatment for multiple sc

108 Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and ant

109 s, including sulforaphane (SFN) and dimethyl fumarate (DMF), are unable to induce a similar response.

110 al of the first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament li

111 Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulat

112 nts switched from E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF 150/150/200/300 mg once daily) to E/

113 up; 4.3 kg [6.7] in the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir group, and 2.3

114 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir group, and 258

115 ravir group, 351 to the tenofovir disoproxil fumarate, emtricitabine, and dolutegravir group, and 351

116 osed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (90

117 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group discontinue

118 351 participants in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group had achieve

119 and 2.3 kg [7.0] in the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group), and was g

120 r group, and 351 to the tenofovir disoproxil fumarate, emtricitabine, and efavirenz group.

121 ially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure proph

122 ventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licens

123 lly suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir

124 number of people taking tenofovir disoproxil fumarate/emtricitabine for HIV prevention.

125 s (PrEP) in the form of tenofovir-disoproxil-fumarate/emtricitabine is being implemented in selected

126 ants were randomized to tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, daruna

127 al density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) sh

128 fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associated with decreased ris

129 tional risk factors and tenofovir disoproxil fumarate exposure.

130 te (BDP; inhaled corticosteroid), formoterol fumarate (FF; long-acting beta(2) agonist), and glycopyr

131 metabolites, including glycine, maltose, and fumarate, following the photoperiod transition.

132 daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented with fever, urinary trac

133 enz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had

134 ine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had

135 daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and the number of adverse e

136 or to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the upper limit of the 9

137 ersus emtricitabine and tenofovir disoproxil fumarate for HIV prevention.

138 pies were emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in P007; abacavir/lamivudine (ABC/3TC

139 (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

140 lated emtricitabine and tenofovir disoproxil fumarate (FTC/TDF).

141 carboxylic acid cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, tryptop

142 n the emtricitabine and tenofovir disoproxil fumarate group (0.34 infections per 100 person-years [0.

143 nd -0.10% (3.39) in the tenofovir disoproxil fumarate group (between-group difference 2.43% [95% CI 1

144 nd -0.73% (3.21) in the tenofovir disoproxil fumarate group (difference 2.04% [1.17-2.90]; p<0.0001).

145 (2%) participant in the tenofovir disoproxil fumarate group had an adverse event that was considered

146 lets (emtricitabine and tenofovir disoproxil fumarate group).

147 up; and one (2%) in the tenofovir disoproxil fumarate group).

148 n the emtricitabine and tenofovir disoproxil fumarate group).

149 lgia (four [7%]) in the tenofovir disoproxil fumarate group.

150 enz, emtricitabine, and tenofovir disoproxil fumarate group.

151 to fumarate (AspA, FumABC), are required for fumarate/H(2)-dependent initial growth.

152 and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 50 copies per mL HIV-1

153 or IDH2) genes, or germline mutations in the fumarate hydratase (FH) and succinate dehydrogenase gene

154 Loss of the tricarboxylic acid cycle enzyme fumarate hydratase (FH) associates with a malignant form

155 ation of the tricarboxylic acid cycle enzyme fumarate hydratase (FH) causes hyperaccumulation of fuma

156 HLRCC), a type of kidney cancer that harbors fumarate hydratase (FH)-inactivating mutations and has e

157 In this study, we investigated the role of fumarate hydratase (Fh1), a key component of the mitocho

158 Mycobacterium tuberculosis (Mtb) fumarate hydratase (fumarase) is a highly conserved esse

159 Fumarate hydratase (fumarase), a vulnerable component of

160 tic paraplegia, giant axonal neuropathy, and fumarate hydratase deficiency.

161 the genes encoding succinate dehydrogenase, fumarate hydratase or isocitrate dehydrogenase, can dysr

162 Importantly, loss of function of fumarate hydratase, a tumor suppressor and TCA cycle com

163 ductions in mitofusin1, peroxiredoxin 4, and fumarate hydratase.

164 gene that encodes for the TCA cycle enzyme, fumarate hydratase.

165 safety of Fluticasone propionate/formoterol fumarate hydrate (FP/FM) was evaluated in pediatric pati

166 tion of new myelin formation with clemastine fumarate improves remote memory recall and promotes fear

167 inate, which consumes aspartate and releases fumarate in a manner involving fatty acid oxidation and

168 or to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bone mineral density an

169 lpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive HIV controllers (N = 35), defined

170 ivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppression and was well t

171 A gain-of-function led to an accumulation of fumarate in PPBL B cells, which engaged the KEAP1-Nrf2 s

172 The concentration of fumarate increased until the 3rd-5th day after thawing a

173 Simultaneously, fumarate increases ferritin gene transcription by activa

174 We inject the hyperpolarized [1-(13)C]fumarate into cell suspensions and track the metabolism.

175 and acceptability of a tenofovir disoproxil fumarate intravaginal ring used continuously with monthl

176 Thus Osm1/fumarate is a new electron acceptor couple in the mitoch

177 Fumarate is a tricarboxylic acid cycle metabolite whose

178 ficant when the enzyme is fully reduced, and fumarate is absent.

179 with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisition of HIV

180 to FliG enhances clockwise rotation and how fumarate is involved in this activity have remained puzz

181 Diroximel fumarate is metabolised to monomethyl fumarate, the acti

182 We show that fumarate is produced in 89% yield, with succinate as a s

183 As fumarate is scarce in the gut, the source of this electr

184 how that the FrdA subunit in the presence of fumarate is sufficient for binding to FliG and for clock

185 ylates, and to succinate (K(d) = 110 nM) and fumarate (K(d) = 400 nM).

186 da, and receiving daily tenofovir disoproxil fumarate/lamivudine were recruited.

187 7 years, and HbA(1c) 7.9 +/- 1.2%) had lower fumarate levels and higher threonine, serine, proline, a

188 Higher baseline fumarate levels and lower baseline amino acid levels-asp

189 lacking mitochondrial Fh1 (which had normal fumarate levels but defective maximal mitochondrial resp

190 of extramitochondrial Fh1 (which normalized fumarate levels but not maximal mitochondrial respiratio

191 teine residues sensitive to the reduction in fumarate levels caused by genetic reintroduction of acti

192 ession can be upregulated by accumulation of fumarate, likely by depleting cells of GSH antioxidant c

193 e metabolites including alpha-KG, succinate, fumarate, malate, and citrate were observed in TGF-beta1

194 rate, isocitrate, 2-oxoglutarate, succinate, fumarate, malate, and oxaloacetate) were tested for thei

195 Thus, we identify novel roles for fumarate metabolism in HSC maintenance and hematopoietic

196 tricarboxylic acid (TCA) cycle and cytosolic fumarate metabolism, in normal and leukemic hematopoiesi

197 issue is predominantly exposed to monomethyl fumarate (MMF), the bioactive metabolite of DMF, which c

198 HIV infection with oral tenofovir disoproxil fumarate monotherapy or combined tenofovir disoproxil fu

199 fection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/em

200 4) or emtricitabine and tenofovir disoproxil fumarate (n=2693).

201 namide (n=111 [66%]) or tenofovir disoproxil fumarate (n=56 [34%]).

202 croscopy in vivo that the mechanism by which fumarate-occupied FrdA enhances clockwise rotation invol

203 etabolites 2-hydroxyglutarate, succinate and fumarate occur in human malignancies owing to somatic mu

204 drug (1S,3'R)-[2',2',3'-(2)H(3)]-solifenacin fumarate on a preparative scale.

205 tors: emtricitabine and tenofovir disoproxil fumarate or abacavir and lamivudine.

206 in several metabolite pools such as malate, fumarate or citrate, and flux calculations suggest the i

207 on targeting MC degranulation with ketotifen fumarate or inhibition of MC-derived tryptase with APC 3

208 ween a pyrazinone and commercially available fumarate or maleate precursors is reported.

209 was observed after intratumoral injection of fumarate or PBS.

210 Treatment of HLRCC cells with dimethyl fumarate or PKM2 activators altered PKM2 oxidation level

211 mtricitabine and either tenofovir disoproxil fumarate or tenofovir alafenamide), with a third regimen

212 bacavir sulphate (ABC), tenofovir disoproxil fumarate, or tenofovir alafenamide.

213 Importantly, we identified fumarate (p = 1.9 x 10(-2)) as a pertinent metabolite, d

214 eceiving efavirenz with tenofovir disoproxil fumarate (p=0.001) but not those receiving efavirenz wit

215 ti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibi

216 d, the effectiveness of tenofovir disoproxil fumarate plus emtricitabine varies across populations; t

217 nt or oral coformulated tenofovir disoproxil fumarate plus emtricitabine.

218 with emtricitabine and tenofovir disoproxil fumarate) previously recommended by WHO.

219 the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against s

220 ever, succinate concentrations and succinate/fumarate ratios were lower in turtle than in mouse heart

221 ovements in growth under increased glutamate:fumarate ratios.

222 Its concentration followed the same trend as fumarate reaching its maximal concentration on the 3rd-5

223 arate (DMF) delivered to cells or endogenous fumarate reacts with gasdermin D (GSDMD) at critical cys

224 fumarate, the active metabolite of dimethyl fumarate, reduces circulating lymphocytes and modifies t

225 e Escherichia coli Complex II homolog quinol:fumarate reductase (QFR, FrdABCD) catalyzes the intercon

226 te transmits its effect to the motor via the fumarate reductase complex (FrdABCD), shown to bind to F

227 e show that flavinylation of a member of the fumarate reductase subfamily allows this enzyme to recei

228 n in which rhodoquinone (RQ) is required for fumarate reduction and ATP production.

229 Fumarate reduction yields succinate, which is exported b

230 which contributes to proton shuttling during fumarate reduction, for detailed biophysical and structu

231 of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%, 95.001% CI -5.9 to 1

232 dy drug and were on the tenofovir disoproxil fumarate regimen before screening were included in prima

233 opinavir/ritonavir, and tenofovir disoproxil fumarate, respectively.

234 ows S. Typhimurium to harvest energy by H(2)/fumarate respiration in the microbiota-colonized gut.

235 The C(4)-dicarboxylate (fumarate) responsive sensor kinase DcuS of Escherichia c

236 assigned to receive the tenofovir disoproxil fumarate ring and five were assigned to receive the plac

237 ed with baseline in the tenofovir disoproxil fumarate ring group but not the placebo group.

238 Two participants in the tenofovir disoproxil fumarate ring group completed 3 months of continuous rin

239 ts were reported in the tenofovir disoproxil fumarate ring group.

240 ons is specific to this tenofovir disoproxil fumarate ring or generalisable to other sustained topica

241 mly assigned (3:1) to a tenofovir disoproxil fumarate ring or placebo ring.

242 of expanding access to tenofovir disoproxil fumarate-sparing regimens in resource-limited settings.

243 onsive to DMF treatment, suggesting that the fumarate-stimulating ULBP2/5 pathway is abrogated in the

244 carcinoma (RCC) and three oncometabolites - fumarate, succinate and L-2-HG - have been implicated in

245 To date, fumarate, succinate, L-2-hydroxyglutarate (L-2-HG) and D

246 Tenofovir alafenamide fumarate (TAF) co-formulated with elvitegravir (EVG, E),

247 Tenofovir alafenamide fumarate (TAF) co-formulated with elvitegravir (EVG; E),

248 Tenofovir alafenamide fumarate (TAF), a new prodrug of tenofovir and a potenti

249 dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF).

250 rsons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were currently o

251 AF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local sta

252 harmacokinetic study of tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg among a

253 favirenz /emtricitabine/tenofovir disoproxil fumarate (TDF) and dolutegravir/emtricitabine/TDF arms.

254 Oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in

255 REP 2165 combined with tenofovir disoproxil fumarate (TDF) and pegylated interferon alfa-2a (pegIFN)

256 have been marketed, and tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have also

257 ent study, we show that tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), drugs wi

258 mivudine at 300 mg, and tenofovir disoproxil fumarate (TDF) at 300 mg (DOR/3TC/TDF) or to efavirenz a

259 Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro ac

260 Tenofovir disproxil fumarate (TDF) has been shown to affect neurogenesis in

261 nofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simp

262 Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatm

263 Tenofovir disoproxil fumarate (TDF) is one of the nucleotide analogs capable

264 esistance and increased tenofovir disoproxil fumarate (TDF) susceptibility.

265 ts switching from E/C/F/tenofovir disoproxil fumarate (TDF) to E/C/F/TAF.

266 ebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 mo

267 tricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/F and TAF.

268 Replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) improves

269 s receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (PI) (0.18 [

270 ombination therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RN

271 itabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

272 mtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

273 potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States a

274 HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy.

275 nd endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.

276 with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF).

277 ion by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamid

278 PLWH receiving tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/EFV 600 mg with a vir

279 s (DOR/lamivudine [3TC]/tenofovir disoproxil fumarate [TDF] or DOR [100 mg daily] with emtricitabine

280 ompounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine.

281 ial therapy with newer (fingolimod, dimethyl fumarate, teriflunomide, natalizumab, rituximab, ocreliz

282 oximel fumarate is metabolised to monomethyl fumarate, the active metabolite of dimethyl fumarate, re

283 stent with fumC-dependent depletion of local fumarate, the DeltahemB SCV failed to elicit trained imm

284 ns by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks.

285 concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks.

286 The ratios of succinate to glutamate, fumarate to alpha-ketoglutarate, 2HG to glutamate, and D

287 om a regimen containing tenofovir disoproxil fumarate to elvitegravir, cobicistat, emtricitabine, and

288 om a regimen containing tenofovir disoproxil fumarate to one containing tenofovir alafenamide in part

289 r, the EET pathway of cathodic conversion of fumarate to succinate is still under debate.

290 100, 0.002-10, and 0.002-5 uM for succinate, fumarate, total 2HG, and D/L-2HG, respectively.

291 Fumarate transmits its effect to the motor via the fumar

292 Clemastine fumarate treatment was associated with fatigue, but no s

293 ry efficacy endpoint was met with clemastine fumarate treatment, which reduced the latency delay by 1

294 ter alternative is to produce hyperpolarized fumarate via PHIP (parahydrogen-induced polarization).

295 de to emtricitabine and tenofovir disoproxil fumarate was established if the upper bound of the 95.00

296 enz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppressi

297 he material into 3D printable poly(propylene fumarate) was utilized to produce thin films and scaffol

298 with emtricitabine and tenofovir disoproxil fumarate were not excluded.

299 redominantly containing tenofovir disoproxil fumarate) were also more likely to experience eGFR decli

300 ne safety compared with tenofovir disoproxil fumarate when used for HIV treatment.